261 related articles for article (PubMed ID: 30601452)
1. Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone.
Mirkin S; Graham S; Revicki DA; Bender RH; Bernick B; Constantine GD
Menopause; 2019 Jan; 26(6):637-642. PubMed ID: 30601452
[TBL] [Abstract][Full Text] [Related]
2. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
Simon JA; Kaunitz AM; Kroll R; Graham S; Bernick B; Mirkin S
Menopause; 2019 May; 26(5):506-512. PubMed ID: 30489424
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.
Constantine GD; Revicki DA; Kagan R; Simon JA; Graham S; Bernick B; Mirkin S
Menopause; 2019 May; 26(5):513-519. PubMed ID: 30516713
[TBL] [Abstract][Full Text] [Related]
4. Improvement in sleep outcomes with a 17β-estradiol-progesterone oral capsule (TX-001HR) for postmenopausal women.
Kagan R; Constantine G; Kaunitz AM; Bernick B; Mirkin S
Menopause; 2018 Dec; 26(6):622-628. PubMed ID: 30586005
[TBL] [Abstract][Full Text] [Related]
5. 17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial.
Kaunitz AM; Bitner D; Constantine GD; Bernick B; Graham S; Mirkin S
Menopause; 2020 Dec; 27(12):1382-1387. PubMed ID: 32740481
[TBL] [Abstract][Full Text] [Related]
6. A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.
Lobo RA; Archer DF; Kagan R; Kaunitz AM; Constantine GD; Pickar JH; Graham S; Bernick B; Mirkin S
Obstet Gynecol; 2018 Jul; 132(1):161-170. PubMed ID: 29889748
[TBL] [Abstract][Full Text] [Related]
7. A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause.
Archer DF; Bernick BA; Mirkin S
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):729-739. PubMed ID: 31282768
[No Abstract] [Full Text] [Related]
8. Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules).
Lobo RA; Liu J; Stanczyk FZ; Constantine GD; Pickar JH; Shadiack AM; Bernick B; Mirkin S
Menopause; 2019 Jul; 26(7):720-727. PubMed ID: 30694918
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms.
Lobo RA; Kaunitz AM; Santoro N; Bernick B; Graham S; Mirkin S
Climacteric; 2019 Dec; 22(6):610-616. PubMed ID: 31364889
[No Abstract] [Full Text] [Related]
10. TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial.
Constantine GD; Simon JA; Kaunitz AM; Pickar JH; Revicki DA; Graham S; Bernick B; Mirkin S
Menopause; 2020 Nov; 27(11):1236-1241. PubMed ID: 33110039
[TBL] [Abstract][Full Text] [Related]
11. Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR).
Mirkin S; Goldstein SR; Archer DF; Pickar JH; Graham S; Bernick B
Menopause; 2020 Apr; 27(4):410-417. PubMed ID: 31913228
[TBL] [Abstract][Full Text] [Related]
12. Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS).
Cintron D; Lahr BD; Bailey KR; Santoro N; Lloyd R; Manson JE; Neal-Perry G; Pal L; Taylor HS; Wharton W; Naftolin F; Harman SM; Miller VM
Menopause; 2018 Feb; 25(2):145-153. PubMed ID: 28832429
[TBL] [Abstract][Full Text] [Related]
13. Effects of estrogen and venlafaxine on menopause-related quality of life in healthy postmenopausal women with hot flashes: a placebo-controlled randomized trial.
Caan B; LaCroix AZ; Joffe H; Guthrie KA; Larson JC; Carpenter JS; Cohen LS; Freeman EW; Manson JE; Newton K; Reed S; Rexrode K; Shifren J; Sternfeld B; Ensrud K
Menopause; 2015 Jun; 22(6):607-15. PubMed ID: 25405571
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials.
Shulman LP; Yankov V; Uhl K
Menopause; 2002; 9(3):195-207. PubMed ID: 11973443
[TBL] [Abstract][Full Text] [Related]
15. 17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review.
Mirkin S; Amadio JM; Bernick BA; Pickar JH; Archer DF
Maturitas; 2015 May; 81(1):28-35. PubMed ID: 25835751
[TBL] [Abstract][Full Text] [Related]
16. Effects of perimenopausal transdermal estradiol on self-reported sleep, independent of its effect on vasomotor symptom bother and depressive symptoms.
Geiger PJ; Eisenlohr-Moul T; Gordon JL; Rubinow DR; Girdler SS
Menopause; 2019 Nov; 26(11):1318-1323. PubMed ID: 31688579
[TBL] [Abstract][Full Text] [Related]
17. Bioidentical Oral 17β-Estradiol and Progesterone for the Treatment of Moderate to Severe Vasomotor Symptoms of Menopause.
Woodis CB; Ghassemi E; McLendon AN
Ann Pharmacother; 2021 Sep; 55(9):1153-1158. PubMed ID: 33345556
[TBL] [Abstract][Full Text] [Related]
18. Relationship between changes in vasomotor symptoms and changes in menopause-specific quality of life and sleep parameters.
Pinkerton JV; Abraham L; Bushmakin AG; Cappelleri JC; Komm BS
Menopause; 2016 Oct; 23(10):1060-6. PubMed ID: 27404028
[TBL] [Abstract][Full Text] [Related]
19. Oral micronized progesterone for vasomotor symptoms--a placebo-controlled randomized trial in healthy postmenopausal women.
Hitchcock CL; Prior JC
Menopause; 2012 Aug; 19(8):886-93. PubMed ID: 22453200
[TBL] [Abstract][Full Text] [Related]
20. Effects of vaginal estradiol tablets and moisturizer on menopause-specific quality of life and mood in healthy postmenopausal women with vaginal symptoms: a randomized clinical trial.
Diem SJ; Guthrie KA; Mitchell CM; Reed SD; Larson JC; Ensrud KE; LaCroix AZ
Menopause; 2018 Oct; 25(10):1086-1093. PubMed ID: 29738424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]